CRISPR CAR T-Cell Therapy Clinical Update
Apr. 27, 2021
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Bioheng Biotech
Main focus: Gene-editing therapies
Company stage: Clinical
Diseases: T-cell acute lymphoblastic leukaemia
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Nanjing, China
Bioheng Biotech is a Chinese clinical stage biotech company. The company's main focus is on developing CAR-T cells for the treatment of T-cell cancers. The company is using its proprietary Cas-V2, an optimised and safer alternative to conventional CRISPR-Cas9 systems, to avoid unwanted double stranded breaks and off-target side effects.
